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Abstract: Hyponatremia is one of the most common electrolyte abnormalities linked to adverse 
outcomes and increased mortality in hospitalized patients. While the differential diagnosis for 
hyponatremia is diverse, most cases stem from arginine vasopressin (AVP) dysregulation, 
where hypoosmolality fails to suppress AVP synthesis and release. The physiological effects 
of AVP are currently known to depend on its interaction with any of 3 receptor subtypes V1A, 
V2, and V1B. Activation of V2 by AVP is the key in renal water regulation and maintenance 
of total body volume and plasma tonicity. Despite the long-recognized problem with excess 
AVP in euvolemic and hypervolemic hyponatremia, traditional therapeutic options have relied 
on nonspeciﬁ  c and potentially problematic strategies. More recently, a new class of drugs, 
introduced as “aquaretics,” has gained great attention among clinicians because of its ability to 
correct hyponatremia via direct competitive inhibition of AVP at V2 receptors to induce renal 
electrolyte-free water excretion. In this paper, we aim to review available clinical data on the 
only FDA-approved aquaretic, dual V1A/V2 receptor antagonist conivaptan, discuss its clinical 
indications, efﬁ  cacy, safety proﬁ  le, and comment on its clinical limitations.
Keywords: conivaptan, hyponatremia, euvolemia, hypervolemia, AVP, AVP receptor 
antagonist
Hyponatremia is the most frequent ﬂ  uid and electrolyte abnormality in hospitalized 
patients, particularly in the intensive care unit setting (DeVita et al 1990; Sedlacek 
et al 2006). In addition to being a potentially life-threatening condition, hyponatremia 
is an independent predictor of death among intensive care unit and geriatric patients 
and those with heart failure, acute ST elevation myocardial infarction, and cirrhosis 
(Arieff et al 1976; Terzian et al 1994; Borroni et al 2000; Lee et al 2000; Bennani et al 
2003; Goldberg et al 2004; Ruf et al 2005).
The syndrome of inappropriate antidiuretic hormone secretion (SIADH), con-
gestive heart failure (CHF), and cirrhosis are common conditions associated with 
abnormal water retention mediated by excess antidiuretic hormone (ADH), also 
known as arginine vasopressin (AVP) irrespective of hypoosmolality. Over the years, 
conventional therapies for these conditions including water restriction, hypertonic 
saline, demeclocycline, and lithium have all proved to have signiﬁ  cant limitations. 
The advent of AVP receptor antagonists has therefore sparked great enthusiasm among 
clinicians as a promising direct therapeutic option for hyponatremia associated with 
dysregulated excess AVP.
While several AVP receptor antagonists are being investigated in clinical trials, 
conivaptan is the ﬁ  rst, and currently, only vasopressin receptor antagonist approved 
by United States Federal Drug Administrations (FDA) for the treatment of hyponatre-
mia. In the current manuscript, we aim to review the literature on the clinical efﬁ  cacy, 
safety, and therapeutic options for the use of conivaptan.Therapeutics and Clinical Risk Management 2008:4(2) 316
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AVP in water and electrolyte 
balance
Overview of   AVP synthesis and release
AVP is produced in the hypothalamus, predominantly in 
the paraventricular and supraoptic nuclei by magnocellular 
neurons. Subsequently, it is transported down axon terminals 
through the supraoptic hypophyseal tract, and eventually 
stored in the posterior pituitary as inactive complexes with 
neurophysins (Davison et al 1981; Ishikawa and Schrier 
2003). AVP release occurs quantally by exocytosis of AVP-
containing secretory granules in response to both osmotic 
and nonosmotic stimuli (Dunn et al 1973).
In the event of an increase in extracellular osmolality, 
water from osmoreceptor cells within the hypothalamus is 
shifted extracellularly to achieve osmotic equilibrium. The 
resultant cell-volume shrinkage or increased intracellular 
osmolality, or both, in turn initiate a cascade of events that 
lead to the augmentation of both AVP synthesis and release 
(Robinson et al 1990). In humans, the osmotic threshold 
for AVP release is approximately 280–290 mOsm/kg 
(280–290 mmol/kg) (Robertson 1987). In addition, for every 
1% increase in serum osmolality, there may be a 2- to 4-fold 
increase in AVP level (Dunn et al 1973).
The synthesis and release of AVP may also be induced by 
nonosmotic stimuli including hypovolemia, a fall in arterial 
blood pressure, neural regulation by various hypothalamic 
neurotransmitters and neuropeptides, and many pharmaco-
logical agents. Endogenous agents including acetylcholine, 
angiotensin II, histamine, bradykinin, and neuropeptide Y 
have all been implicated in the stimulation of AVP release 
(Sladek 1983; Baylis 1989). Pharmacological agents such 
as morphine, nicotine, chemotherapeutic agents, tricyclic 
antidepressants, anticonvulsants, cloﬁ  brate, and chlorprop-
amide and clinical conditions including nausea, vomiting, 
pain, and hypoglycemia also may play a role (Sladek 1983; 
Baylis 1989).
AVP receptor subtypes
AVP exerts its actions through three subtypes of G-protein – 
coupled membrane receptors including V1A (vascular), V2 
(renal), and V1B (pituitary), also denoted as V3 in the 
literature.
V1A receptors are found on vascular smooth muscle, 
liver, kidneys, reproductive organs, spleen, adrenal cortex, 
and platelets. The vasoconstrictive, mitogenic, and possibly 
platelet aggregative and hypercoagulable actions of AVP 
through V1A have been suggested to potentially contribute 
to the pathogenesis and progression of arterial hypertension, 
heart failure, and atherosclerosis (Thibonnier et al 2001).
V2 receptors are expressed primarily in basolateral 
membranes of renal cortical and medullary collecting ducts 
and, to a lesser extent, distal tubules. Binding of circulating 
AVP to the G-protein-coupled V2 receptors on the basolateral 
membranes of principal cells in the collecting ducts activates 
adenylyl cyclase, thereby enhances the production of cyclic 
adenosine monophosphate (cAMP) and the subsequent 
activation of protein kinase A. The down-stream effect is 
enhanced production and trafﬁ  cking of the water channels 
aquaporin-2 to the luminal membranes to facilitate water 
reabsorption into the hypertonic medullary interstitium. 
In effect, the physiological roles of AVP via V2 receptors 
include maintenance of plasma tonicity and blood pressure 
and volume regulation (Thibonnier et al 2001; Lee et al 
2003).
V1B (or V3) receptors are found predominantly in the 
anterior pituitary corticotroph cells and, to a lesser extent, 
the brain, kidney, pancreas, and adrenal medulla. Physiologi-
cally, activation of V3 receptors is associated with adreno-
corticotropic hormone and β-endorphin release (Thibonnier 
et al 2001).
AVP: V2 interaction and water 
homeostasis
Regulated state
While water homeostasis is dependent on osmotically 
active solutes at the cellular level, total body water balance 
is regulated by the thirst center and renal water excretion 
(Verbalis 2003).
Renal free water excretion is dependent on the integ-
rity of nephron-diluting segments, a hypertonic medullary 
interstitium, and intact AVP activity at the collecting ducts 
(Figure 1). For renal water excretion to occur, free water is 
ﬁ  rst produced in the nephron-diluting segment, the thick 
ascending loop of Henle, by salt extractions from the lumen 
through the sodium potassium-2 chloride (NKCC) cotrans-
porter. Intraluminal free water is produced with this process 
because water cannot diffuse across the luminal surface in 
parallel with salt uptake due to the unique water-impermeable 
characteristic of this diluting segment. Reabsorption of salt 
without water continues to occur in the distal convoluted 
tubule, where dilution of urine is maximized. While free 
water is produced within the lumen, salt uptake by previous 
nephron segments concomitantly creates and maintains the 
high tonicity within the medullary interstitium. Subsequent 
delivery of the intraluminal free water to the collecting Therapeutics and Clinical Risk Management 2008:4(2) 317
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ducts may be either reabsorbed or excreted into urine. In 
the presence of AVP and an intact hypertonic medullary 
interstitium, AVP, mediated by V2 receptors, upregulates 
the expression and trafﬁ  cking of aquaporin-2 to the luminal 
side of the collecting tubules and allows water to be reab-
sorbed efﬁ  ciently into a more tonic medullary milieu. AVP-
facilitated free-water reabsorption at the collecting tubules 
reduces and concentrates the ﬁ  nal urine volume (Verbalis 
2003). In the absence of AVP, the free water produced from 
the diluting segment is excreted and is reﬂ  ected clinically as 
a high urine output with low osmolality.
Dysregulated state:   AVP excess and hyponatremia
In the dysregulated state where AVP is excessively produced 
and released irrespective of hypoosmolality, profound water 
retention and hyponatremia may occur (Baylis 2003).
In the setting of hypovolemia where there is great volume 
loss or fall in arterial blood pressure, AVP is appropriately 
upregulated to enhance both thirst and renal water retention 
in an effort to restore volume and arterial blood pressure. 
Excessive free water uptake in this case, however, can easily 
lead to hyponatremia (Hew-Butler et al 2005).
In cases of CHF, where the reduced cardiac function 
fails to effectively drive the blood volume from the venous 
to arterial circulation to maintain the effective arterial 
volume, AVP is upregulated to induce cardiomyocyte 
hypertrophy and vasoconstriction via V1A and enhance 
renal water retention via V2, as compensatory mechanisms 
to increase the effective arterial volume. With further 
deterioration in heart failure, however, the successive and 
cumulative compensatory upregulation of AVP paired with 
unrestricted free water intake can lead to the development 
of hypervolemia and hyponatremia (Bartter and Schwartz 
1967). Similarly, patients with cirrhosis or nephrosis who 
have poor arterial pressure because of peripheral vasodila-
tion, relatively low intravascular oncotic pressure, or both, 
may also progressively develop an upregulated AVP state 
irrespective of osmolality. In the setting of unrestricted free 
water intake, hypervolemia and hyponatremia develop as a 
result of the excessive AVP-driven renal free-water reabsorp-
tion (Andreoli 2000; Cardenas and Arroyo 2003).
Euvolemic hyponatremia accounts for 60% of all forms 
of chronic hyponatremia, of which SIADH, a disorder in 
which AVP release is independent of volume, blood pressure, 
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Figure 1 Renal-free water metabolism. The presence of AVP favors renal free water reabsorption whereas its absence favors water excretion.
Abbreviations: PT, proximal tubule; TAH, thick ascending limb loop of Henle; DCT, distal convoluted tubule; CT, collecting tubule; NCCK, sodium potassium-2 chloride 
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and osmotic control, predominates (Zerbe et al 1980; Baylis 
2003). The major categories of illnesses associated with 
SIADH include neoplasm, neurological disease or trauma, 
pulmonary disorders, and various physiologically stressful 
states such as nausea, vomiting, pain, and anxiety. In addi-
tion, SIADH may be induced by various pharmacological 
agents including tricyclic antidepressants and anticonvulsants 
(Zerbe et al 1980; Fraser and Arieff 1997; Adrogué and 
Madias 2000; Baylis 2003).
Traditional therapeutic options 
for hyponatremia
Ethanol was the ﬁ  rst agent recognized to inhibit ADH secre-
tion. The therapeutic potential of ethanol in the management of 
hyponatremia, however, is unacceptable because of the multiple 
medical complications associated with its use (Berl 2007).
Prior to 2005, common treatment options for patients 
with hyponatremia, included sodium supplementation, water 
restriction, and in some cases, pharmacological agents such as 
demeclocycline, lithium, and loop diuretic therapy. Although 
these therapeutic options may be generally effective, they are 
not without limitations (Table 1).
For hypovolemic hyponatremia, normal saline infusion 
is most effective and is undoubtedly the therapy of choice. 
Normal saline infusion, however, may not be effective or 
even detrimental in severe cases of SIADH (ie, urine osmolal-
ity much greater than 300 mOsm/kg), where avid renal free 
water reabsorption can, in essence, extract free water from 
the normal saline infused for reabsorption at the collecting 
tubules, a phenomenon known as “desalination.” The excess 
free water reabsorbed can exacerbate the existing hyponatre-
mia and induce serious neurological sequelae.
In patients with hypervolemic hyponatremia due to CHF, 
cirrhosis, or nephrosis, saline infusion may worsen the exist-
ing hypervolemia. Water restriction with or without concomi-
tant diuretic administration in patients with euvolemic and 
hypervolemic hyponatremia, on the other hand, may lead to 
a slow response, less predictable outcomes, and occasionally, 
serious hypovolemic complications.
In chronic hyponatremia where ﬂ  uid restriction is not 
tolerated, demeclocycline, may be used to induce free water 
excretion via the reduction of renal medullary adenylate 
cyclase activity, the mediator for a full vasopressin effect 
on the collecting system (Singer and Rotenberg 1973). The 
use of demeclocycline, however, is limited by inconsistent 
results and adverse effects including azotemia, photosensi-
tivity, and nausea. In addition, its use is contraindicated in 
patients with cirrhosis and renal failure (Miller et al 1980; 
Fried and Palevsky 1997).
Lithium, an agent commonly prescribed for patients with 
manic depressive patients, has also been previously suggested 
to be a possible therapeutic agent in the management of 
chronic hyponatremia. The mechanism of action is thought 
to be via the downregulation aquaporin 2 in collecting tubules 
(Robbenet al 2006). The chronic use of lithium, however, is 
limited by nephrotoxicity (Markowitz et al 2000).
Loop diuretics are effective in inhibiting renal free 
water production and reabsorption and thus potentially ben-
Table 1 Traditional therapeutic options for hyponatremia
Treatment options Mechanisms Limitations
Ethanol Inhibits ADH secretion Alcoholism and associated complications
Sodium supplementation Increases total body sodium May exacerbate hyponatremia in severe SIADH where kidneys can 
“extract” and reabsorb free water from normal saline
Volume overload in hypervolemic conditions
Water restriction Decreases free water availability for renal 
reabsorption
Inadequate volume intake, volume depletion, acute tubular necrosis
Demeclocycline Reduces vasopressin effect by inhibiting the 
production of its mediator, cAMP
Inconsistent results
Photosensitivity
Nausea, vomiting
Azotemia
Contraindicated in patients with cirrhosis and renal failure
Lithium Downregulation of aquaporin 2 Nephrotoxicity
Loop diuretics Inhibits free water production and reduces 
medullary tonicity for effective water reabsorption
Volume depletion 
Unpredictable results
Abbreviations: ADH, antidiuretic hormone; SIADH, syndrome of inappropriate ADH; cAMP, cyclic adenosine monophosphate.Therapeutics and Clinical Risk Management 2008:4(2) 319
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eﬁ  cial in the management of euvolemic and hypervolemic 
hyponatremia. Unfortunately, excessive volume depletion 
and poor response predictability may be problematic.
Given the potential adverse effects with existing 
therapeutic options for hyponatremia, the introduction of 
vasopressin receptor antagonists as a class of drug that can 
directly induce electrolyte-free water excretion to correct 
hyponatremia has gained great interests among clinicians. 
Indeed, the advent of vasopressin receptor antagonists has 
given rise to the term, “aquaretics,” as opposed to “diuret-
ics,” to denote agents that can induce “electrolyte-free” 
water excretion.
AVP receptor antagonists
The safety and efﬁ  cacy of AVP receptor antagonists in the 
treatment of both euvolemic and hypervolemic hyponatremia 
have been evaluated in multiple clinical trials. AVP receptor 
antagonists directed at V2 receptors (lixivaptan, tolvaptan 
and satavaptan) are currently being investigated for clinical 
use in patients with euvolemic and hypervolemic hypona-
tremia. Lixivaptan, an oral V2 receptor antagonist, has been 
shown to be effective in raising serum sodium concentrations 
in patients with CHF, SIADH, and cirrhosis with ascites. 
Tolvaptan, another oral V2 receptor antagonist, has also been 
studied extensively and shown to be effective in inducing 
aquaresis and improving serum sodium concentrations in 
patients with CHF (reviewed in Pham et al 2006). Satavap-
tan, is the latest oral V2 receptor antagonist introduced into 
clinical trials for the treatment of hyponatremia in SIADH 
patients (Soupart et al 2006) (Table 2). To date, all of these 
agents have been shown to effectively promote “aquaresis,” 
the electrolyte-sparing excretion of free water and thereby 
improve hyponatremia (Serradeil-Le Gal et al 2002).
Similar to all V2 receptor antagonists, conivaptan, a 
dual V1A/V2 receptor antagonist, has also been studied 
extensively in both euvolemic and hypervolemic patients. 
Currently, however, conivaptan is the only FDA approved 
aquaretic in the United States for use in hospitalized patients 
with euvolemic and hypervolemic hyponatremia.
Conivaptan
Chemical structure and molecular 
mechanism of action
Conivaptan hydrochloride (Vaprisol®, Astellas Pharma 
US, Inc.), is chemically [1,1•biphenyl]-2-carboxamide, 
N-[4-[(4,5-dihydro-2-methylimidazo[4,5-d][1]benzazepin-
6(1H)-yl)carbonyl]phenyl]-,monohydrochloride (Figure 2). 
Conivaptan inhibits AVP by competitively and reversibly 
binding to selected AVP receptors without interacting with 
the receptors’s active sites. Although conivaptan has high 
afﬁ  nities for both V1A and V2 receptors, radioligand compe-
tition binding assays revealed a tenfold higher afﬁ  nity for V2 
than that for V1A receptors (Burnier et al 1999). Because of 
the higher afﬁ  nity for V2, conivaptan is predominantly used 
for its V2-associated aquaretic effect. Nonetheless, conivap-
tan inhibition of V1A receptors can theoretically result in 
clinically signiﬁ  cant effects that must be considered among 
a subset of hyponatremic patients. As V1A stimulation is 
associated with vasoconstrictive, mitogenic, and possibly 
platelet aggregative effects, its inhibition can be potentially 
beneﬁ  cial for patients with CHF with concomitant hyper-
tension and atherosclerotic disease. In contrast, the very 
same effects derived from V1A inhibition can be harmful 
for hypotensive patients or cirrhotic patients with dilated 
splanchnic beds and variceal bleeds. Further dilatation of 
the splanchnic bed and interference with platelet aggrega-
tion by V1A inhibition could exacerbate variceal bleeding 
complications. Hypothermia due to skin vasodilatation is 
another theoretical concern among those at risk.
Pharmacokinetics and metabolism
The pharmacokinetics of conivaptan have been evaluated 
in both oral and intravenous forms in healthy individuals 
and patients with various euvolemic and hypervolemic 
conditions including CHF. In healthy individuals, oral 
conivaptan at 60 mg has been demonstrated to have an 
absolute bioavailability of 44%, Cmax of 664 ng/dL, and t 
½ of 5.6 hours (h) (Burnier et al 1999). In healthy males, 
intravenous conivaptan administered at a 20 mg loading 
Table 2 Overview of AVP receptor antagonists
Agent  Receptor target  Disorders studied in clinical trials
Conivaptan V1A/V2  Euvolemic or hypervolemic hyponatremia (Ghali 2006; Verbalis 2004; Gross 2004) CHF (Udelson 2001)
Lixivaptan V2  CHF (Wong 2003), SIADH (Wong 2003), cirrhosis (Wong 2003; Gerbes 2003)
Tolvaptan V2  CHF (Gheorghiade 2003, 2004)
Satavaptan V2  SIADH (Soupart 2006)
Abbreviations: CHF, chronic heart failure; SIADH, syndrome of inappropriate antidiuretic hormone secretion.Therapeutics and Clinical Risk Management 2008:4(2) 320
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dose over 30 minutes resulted in a mean Cmax of 619 ng/mL 
at the end of the loading dose and Cmin at 12 hours. With a 
continuous infusion of 40 mg/d over 3 days following the 
loading dose, a mean concentration of 188 ng/mL over the 
infusion duration was achieved. The mean terminal elimi-
nation half-life following the infusion was 5.0 hours with a 
mean clearance of 15.2 L/h (46). High intersubject variability 
was noted. Patients with hypervolemia may achieve a lower 
Cmax compared to euvolemic patients when given the same 
loading dose. Of note, the pharmacokinetics of conivaptan 
following either route of administration were non-linear, a 
phenomenon suggested to reﬂ  ect conivaptan’s inhibition of 
its own metabolism (Astellas Pharma US, Inc. 2007).
At therapeutic range, conivaptan is highly protein-bound 
(99%). It is both a substrate and potent inhibitor of the liver 
cytochrome P450 isozyme CYP3A4. The metabolites of 
conivaptan have been shown to retain some pharmacological 
effect (3%–50% V1A and 50%–100% V2 inhibition). With 
rapid drug elimination in most cases, however, the clinical con-
tributions from the metabolites have been shown to be small 
(Burnier et al 1999). Conivaptan elimination has been shown 
to occur predominantly via the gastrointestinal tract, and to a 
lesser extent, urinary route. Special caution must be exercised 
in treating geriatric patients and individuals with renal and 
hepatic impairment because of decreased drug clearance.
Because conivaptan signiﬁ  cantly interacts with the cyto-
chrome P450 isozyme CYP3A4, great caution must be given 
when conivaptan is co-administered with medications that 
can affect or are affected by this system. Co-administration of 
conivaptan can increase plasma concentrations of midazolam, 
simvastatin, digoxin and amlodipine. Co-administration 
of conivaptan with potent inhibitors of CYP3A4, such as 
ketoconazole, itraconazole, clarithromycin, ritanovir, and 
indinavir is contraindicated. Due to concerns for potentially 
serious drug-drug interactions with chronic use, conivaptan 
is only available clinically in the intravenous form for short-
term in-hospital use.
Clinical efﬁ  cacy (Table 3)
Conivaptan in heart failure
As AVP has been shown to be elevated in most patients with 
heart failure and suggested to adversely affect cardiovascular 
outcomes (Rouleau et al 1994), the potential beneﬁ  ts and 
hemodynamic effects of conivaptan in patients with advanced 
heart failure have been examined in several trials (Udelson 
et al 2001; Gross et al 2004; Verbalis et al 2004).
In a large multicenter, randomized, double-blind, 
placebo-controlled trial, Udelson et al (2001) examined 
the acute effects of conivaptan as a dual V1A/V2 inhibitor 
on commonly measured hemodynamic parameters among 
patients with advanced heart failure. The study involved 
patients with symptomatic heart failure (New York Heart 
Association Class III and IV) of at least 3 months duration 
due to left ventricular systolic dysfunction. Eligible patients 
had to be on a standard background therapy for heart failure, 
including at least 1 month of therapy with a loop diuretic and 
an angiotensin converting enzyme inhibitor (unless intoler-
ance was previously demonstrated). At study entry, patients 
were randomized to receive a single dose of placebo, 10, 20, 
or 40 mg of conivaptan intravenously. Randomization was 
stratiﬁ  ed as to whether patients were receiving background 
therapy with β-adrenergic blockers. Hemodynamic and renal 
parameters and vital signs were measured at multiple time 
points (1- to 2-hour intervals) over a 12-hour study period. 
Background diuretics and other medications were held during 
the study period, and ﬂ  uid intake was “restricted” to 250 mL 
every 2 hours.
A total of 142 patients were included in the study. The 
patient sample had an average age of 58.3 ± 2 and consisted of 
76.1% males, 59.2% Caucasians, 35.9% African Americans, 
and 4.9% Hispanics. Eighty-nine percent of the patients were 
classiﬁ  ed as having CHF class III and 11% class IV. Signiﬁ  -
cant beneﬁ  cial alterations in hemodynamics were observed 
to peak during 3–6 hours and maintained, although at a 
decreasing level, over the 12-hour study period. Compared 
to placebo, conivaptan at 20 and 40 mg signiﬁ  cantly reduced 
pulmonary capillary wedge pressure (peak effect: –2.6 ± 
0.7, –5.4 ± 0.7, and –4.6 ± 0.7 mmHg for the placebo, 20, 
and 40 mg groups, respectively, p   0.05) and right atrial 
Figure 2 Structure of conivaptan.
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pressure (peak effect: –2.0 ± 0.4, –3.7 ± 0.4, and –3.5 ± 0.4 
mmHg for the placebo, 20, and 40 mg groups, respectively, 
p   0.05). The fall in pulmonary capillary wedge pressure 
and right atrial pressure was associated with a signiﬁ  cant 
increase in urine output which peaked during the ﬁ  rst four 
hours following the administration of conivaptan (–11 ± 17, 
152 ± 19, and 176 ± 18 mL/h for the placebo, 20, and 40 mg 
groups, respectively, p   0.001). The higher urine output 
in both conivaptan groups was associated with markedly 
lower osmolality compared to that of placebo. With the 
exception of a slight increase in vasopressin level in the 40 
mg/d treatment group, vasopressin levels in general, did not 
change signiﬁ  cantly over the 12 hour study period. Other 
hemodynamic parameters including cardiac index, systemic 
and pulmonary vascular resistance, blood pressure, and heart 
rate did not differ signiﬁ  cantly from placebo. The investiga-
tors, thus concluded that the use of conivaptan in advanced 
heart failure resulted in favorable hemodynamic changes, 
presumably via enhancing aquaresis without affecting blood 
pressure and heart rate. It must be noted, however, that the 
study only examined the acute alterations in hemodynamics 
following a single intravenous dose of conivaptan.
Despite Udelson et al’s encouraging results, 10 Phase 
2/pilot heart failure studies failed to show that the use of 
conivaptan signiﬁ  cantly improved heart failure outcomes 
including length of hospital stay, categorized physical ﬁ  ndings 
of heart failure, ejection fraction, exercise tolerance, functional 
status, or heart failure symptoms compared to placebo (Astel-
las Pharma US, Inc. 2007). The inconsistencies between 
Udelson’s study and all other subsequent studies may have 
reﬂ  ected the very loose ﬂ  uid “restriction” of 250 mL every 
2 hours used in Udelson’s study. In the routine management 
of CHF, ﬂ  uid restriction is typically 50–75 mL/h. The high 
ﬂ  uid intake allowed may have exaggerated the short-term 
beneﬁ  cial aquaretic effects of conivaptan. That is, conivap-
tan may have predominantly helped remove the excess ﬂ  uid 
intake during the study, and not the volume overload from 
the underlying CHF per se. Moreover, the higher ﬂ  uid intake 
allowed may have masked conivaptan-induced adverse effects 
on the various hemodynamic parameters. Net ﬂ  uid balance 
was not reported in the study.
Due to the lack of data documenting positive outcomes 
with the use of conivaptan in CHF patients and, in part, 
concerns for unknown effects of conivaptan on endothelin 
production and neurohormonal systems including the renin 
angiotensin aldosterone system and sympathetic nervous 
system, conivaptan is currently not recommended for CHF 
patients, unless the beneﬁ  t of correcting the associated hypo-
natremia outweighs the potential risk of adverse events.
Conivaptan in euvolemic 
and hypervolemic hyponatremia
The efﬁ  cacy of conivaptan as an aquaretic agent to correct 
hyponatremia has been evaluated in several multicenter-
randomized, double-blind, placebo-controlled trials. In 2004, 
several such studies were presented at the American Heart 
Association Scientiﬁ  c Sessions (Ghali et al 2004; Gross et al 
2004; Verbalis et al 2004).
In the study led by Verbalis in North America, 84 patients 
involving men and women of 18 years of age or greater with 
“euvolemic and hypervolemic hyponatremia” including 
patients with CHF with serum sodium ([Na+]) 115 to less 
than 130 mEq/L were recruited. Subjects were randomized to 
receive placebo or 20 mg of conivaptan as a bolus intravenous 
dose, followed by a continuous infusion of 40 or 80 mg per 
day for 4 days (Verbalis et al 2004). At baseline, serum [Na+] 
were 124.3 ± 4.9, 123.3 ± 4.7, and 124.8 ± 3.4 mEq/L for 
the placebo, 40 mg/day, and 80 mg/day groups respectively, 
p = NS. The least square mean changes in serum [Na+] at day 
4 for the 3 respective groups were 2.0 ± 0.8, 6.8 ± 0.8, and 9.0 
± 0.8 mEq/L. Accordingly, the number (%) of patients achiev-
ing 6 mEq/L or more increase in serum [Na+] from baseline 
Table 3 Clinical use of conivaptan
• Efﬁ  cacy and safety proﬁ  le have been shown to be acceptable in short-term studies; short-term use may be considered:
 –  Euvolemic  hyponatremia
 –  Hypervolemic  hyponatremia
• Safety  proﬁ  le unclear; use not recommended:
  –  Congestive heart failure
   •  Use may be considered if beneﬁ  ts of hyponatremia correction outweigh potential risks for adverse effects
• Safety  proﬁ  le likely not favorable; use not recommended:
 –  Cirrhosis
• Potential  beneﬁ  ts; more data needed; use not yet recommended:
  –  Polycystic kidney disease
  –  Nephrogenic diabetes insipidus, type 2Therapeutics and Clinical Risk Management 2008:4(2) 322
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or normalization of [Na+] (deﬁ  ned as  135 mEq/L) were 
6 (20.7%), 20 (69%); p   0.01, and 23 (88.5%); p   0.001 
for the 3 respective groups. The median time from the ﬁ  rst 
dose to 4 mEq/L increase in serum [Na+] was 23.7 hours and 
23.4 hours for the conivaptan 40 mg/day and 80 mg/d groups, 
respectively. In addition, the mean changes in effective water 
clearance from baseline on day 1 were –332.3 ± 434.1, 1984 ± 
1559.4; p   0.05, and 1759.4 ± 1748.3 ml; p   0.05 for the 
3 respective groups. Based on the data, Verbalis et al (2004) 
concluded that during the short-term study, conivaptan sig-
niﬁ  cantly improved serum [Na+] and water clearance within 
24 hours in their patients with euvolemic and hypervolemic 
hyponatremia including those with CHF.
In a different study conducted across 17 centers in 
Europe, Gross et al (2004) evaluated the efﬁ  cacy of oral 
conivaptan in the treatment of euvolemic and hypervol-
emic hyponatremia including patients with CHF. Recruited 
patients were 18 years of age or greater with serum [Na+] of 
115 to  130 mEq/L and plasma osmolality  290 mOsm/kg 
H2O. At study entry, patients were randomized to receive 
placebo, 40, or 80 mg/day orally in 2 divided doses for 
5 days. The study sample involved 55 men and 28 women, 
52 of whom had euvolemic and 31 hypervolemic hyponatre-
mia. At baseline, serum [Na+] were 125.6 ± 3.9, 125.1 ± 5.1, 
and 125.6 ± 3.6 mEq/L for the placebo, conivaptan 40 mg/d, 
and 80 mg/d groups, respectively, p = NS. The least squares 
mean change in serum [Na+] on day 5 for the 3 respective 
groups were 1.0 ± 0.9, 6.8 ± 0.9, and 8.8 ± 0.9 mEq/L. 
The number (%) of patients achieving 6 mEq/L or greater 
increase in serum [Na+] or normalization of [Na+] (deﬁ  ned 
as [Na+]  135 mEq/L) during the treatment period was 
6 (20%), 18 (67%); p   0.001, and 23 (89%); p = 0.0001, 
for the 3 respective groups. Most importantly, the increase in 
serum [Na+] among the conivaptan treated groups appeared 
to be dose-dependent. The median time from the ﬁ  rst dose 
to 4 mEq/L increase in serum [Na+] was 23.5 hours (95% 
CI 12–24 hours) for the 40 mg/d group and 8.7 hours (95% 
CI 4–24 hours) for the 80 mg/d group. The improvement in 
serum [Na+] was reﬂ  ected in signiﬁ  cantly better effective 
water clearance (–12 ± 464, 974 ± 1233, and 1342 ± 1143 mL 
for the placebo, conivaptan 40 mg/d, and 80 mg/d groups, 
respectively). The investigators thus concluded that during 
the 5-day study period, oral conivaptan resulted in signiﬁ  -
cant increases in serum [Na+] and effective water clearance 
within the ﬁ  rst day of treatment.
Most recently, Ghali et al (2006) published the results 
from their randomized, double-blind, placebo-controlled 
trial conducted across 21 sites in the United States, Canada, 
and Israel, involving the efﬁ  cacy of oral conivaptan in the 
treatment of patients with euvolemic and hypervolemic 
hyponatremia. The study involved hospitalized patients of 
at least 18 years of age who had a serum [Na+] of 115 to less 
than 130 mEq/L, plasma osmolality less than 290 mosmol/kg 
H2O, and no evidence of extracellular volume depletion. 
Recruited patients were randomized to receive placebo, 
40, or 80 mg/d of conivaptan orally in 2 divided doses for 
5 days. Close monitoring of clinical laboratory and safety 
proﬁ  le parameters occurred throughout the study period 
and at 6–9 days following the conclusion of the treatment 
period. Fluid intake was limited to 2.0 L/d. The main outcome 
measure was the change in serum [Na+] area under the curve 
from baseline.
The study involved a sample size of 74 patients who had 
an average age of 69.3 years (range 35–94). The underly-
ing conditions thought to be associated with hyponatremia 
included chronic obstructive pulmonary disease (4.2%), 
malignancy (11.3%), idiopathic (21.0%), CHF III and IV 
(45.0%), and other (22.5%). The randomization process 
resulted in 23, 24, and 27 patients in the placebo, 40, and 80 
mg/d groups, respectively. The baseline serum [Na+] were 
123.4 ± 4.1, 125.3 ± 3.5, and 125.4 ± 4.0 mEq/L in the 3 
respective groups, p = NS.
The changes from baseline in serum [Na+] AUC [least-
squares mean (SE) mEq*h/L] were 309.2 (94.8), 621.3 (89.0), 
and 836.2 (87.8) in the 3 respective groups, p-values for the 
treated groups compared to placebo were 0.03 and  0.001 
for the 40 and 80 mg/d groups, respectively. The least-squares 
mean total time for serum [Na+] to increase  4 mEq/L above 
baseline were 46.5 (9.0), 69.8 (8.5), and 88.8 (8.4) for the 3 
respective groups, with p-values of 0.103 and 0.001 for the 40 
and 80 mg/d groups compared to placebo, respectively. The 
percentage of patients with conﬁ  rmed normalization of serum 
[Na+] (deﬁ  ned as  135 mEq/L) or increase of  6 mEq/L 
from baseline was 48, 71, and 82% in the 3 respective groups, 
with p = 0.014 for the 80 mg/d group compared to placebo. 
In addition, the effective water clearance on day 1 of the 
study as well as its cumulative change over the 5-day treat-
ment period were signiﬁ  cantly higher in both conivaptan 
groups compared to placebo. The increase in aquaresis by 
both conivaptan treatment groups was in accordance with the 
signiﬁ  cant fall in urine osmolality in both groups compared 
to that of placebo.
Based on currently available studies, conivaptan appears 
to be effective in inducing aquaresis to correct hyponatre-
mia with short-term use in both hypovolemic and hyper-
volemic hyponatremic patients including those with CHF. Therapeutics and Clinical Risk Management 2008:4(2) 323
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Nevertheless, as previously discussed, the use of conivaptan 
in CHF is not routinely recommended due to inadequate data 
and unclear safety issues.
Conivaptan in cirrhosis
As previously discussed, it is not advisable to use conivaptan 
in patients with cirrhosis because V1A inhibition could exac-
erbate splanchnic vasodilatation and interfere with platelet 
aggregation, thus promote variceal bleeds. Whether the use 
of pure or relatively pure V2 receptor antagonists is safe in 
these conditions is not known.
Other potential uses of conivaptan: 
PCKD, nephrogenic DI
Polycystic kidney disease (PCKD) is one of the most recog-
nized inherited kidney diseases characterized by the formation 
of renal cysts from tubular epithelial cells of predominantly 
collecting duct origin. The underlying genetic defects have 
been identiﬁ  ed to involve the polycystin-encoding PKD1 and 
PKD2 for autosomal dominant and the ﬁ  brocystin-encoding 
PKHD1 for autosomal recessive polycystic kidney disease. 
Defects of the involved proteins in tubular epithelia are 
thought to result in cellular de-differentiation, excessive ﬂ  uid 
secretion, and proliferation, hence, cyst formation. While 
alterations in many cellular components and processes asso-
ciated with the primary protein defects have been implicated 
in the pathogenesis of PCKD, renal accumulation of cAMP 
has been observed as a common factor in most models of 
PCKD (reviewed in Torres and Harris 2006). In the principal 
cells of collecting ducts, it is known that vasopressin stimu-
lates adenylyl cyclase via V2 receptors to form cAMP. The 
introduction of V2 receptor antagonists has therefore led to 
ongoing investigations into the role of these agents in slowing 
the progression of human PCKD. Preliminary data in animal 
models of PKD have revealed reduction in kidney weight, cyst 
volume, and renal ﬁ  brosis in association of reductions in renal 
cAMP levels with the use of V2 receptor antagonists (Gattone 
et al 2003; Torres et al 2004; Torres and Harris 2006).
Congenital nephrogenic diabetes insipidus (NDI) is a 
condition characterized by the loss of AVP-mediated renal free 
water reabsorption. The pathogenic mechanisms may involve 
mutations leading to reduced AVP binding to V2 receptors 
(type 1), misfolding hence reduced trafﬁ  cking of V2 receptors 
from the endoplasmic reticulum to cell surface (type 2), or direct 
defect in the transcription of V2 receptors (type 3) (Fujiwara 
and Bichet 2005). In a recent study, Bernier et al provided 
data to suggest that the use of conivaptan may be beneﬁ  cial 
in the treatment of NDI in patients with type 2 mutations. The 
investigators demonstrated that conivaptan can improve cell 
surface expression of the mutated misfolded V2 receptors 
in cultured cell systems. It was suggested that the agent acts 
as a pharmacologic chaperone to improve trafﬁ  cking of the 
mutated misfolded V2 receptors to the cell surface where they 
can interact with AVP to enhance free water retention (Bernier 
et al 2006). Further conﬁ  rmatory studies are warranted.
Clinical safety (Table 4)
Minor adverse effects
The most common adverse effects reported for the short-
term use of conivaptan include headaches, increased thirst, 
pyrexia, constipation, nausea, and phlebitis at the site of drug 
infusion (Astellas Pharma US, Inc. 200).
Serious adverse effects
Minimal to clinically signiﬁ  cant fall in blood pressure to the 
extent of postural hypotension have been reported (Udelson 
et al 2001; Ghali et al 2006). In a study involving euvolemic 
and hypervolemic hyponatremic patients, Ghali et al (2006) 
reported signiﬁ  cant hypotension in two patients with severe 
cardiomyopathy, one of whom had concomitant conven-
tional diuretic therapy, and another patient with presumed 
polydipsia-induced hyponatremia. In our opinion, the use of 
combined conventional diuretics and V2 receptor antagonists 
must be carefully evaluated, especially in the setting involv-
ing patients with tenuous cardiac function and blood pressure. 
In addition, the use of V2 receptor antagonists should be 
contraindicated in ﬂ  uid-restricted patients with polydipsia-
induced hyponatremia.
One of the most concerning issues with the use of any V2 
receptor antagonist in the treatment of hyponatremia is the 
rate of correction of serum [Na+]. While most patients were 
reported to do well with conivaptan, it is concerning to note 
that 5 out of 51 patients who received conivaptan 40–80 mg/d 
from Ghali et al’s (2006) study had a rapid serum [Na+] 
correction, apparently as fast as 14 mEq/L within 4 hours 
of treatment. While no serious neurological sequelae has 
been reported from the rapid rate of correction to date, the 
development of osmotic demyelination syndrome remains 
a possibility with post-marketing use.
Hypokalemia, reported to occur in up to 22% of patients 
receiving conivaptan, is another concerning side effect that 
must be recognized (VHA 2006; Landwehr and Huling 
2007). Particular caution must be given to patients with CHF 
and those with underlying total body potassium depletion to 
avoid potentially life-threatening arrhythmias, rhabdomyoly-
sis, or other hypokalemic-related metabolic complications. Therapeutics and Clinical Risk Management 2008:4(2) 324
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We speculate that conivaptan induces renal potassium loss 
via enhanced urinary ﬂ  ow and facilitated potassium secretion 
at the collecting tubules.
Unknown potential adverse effects
Rebound hyponatremia may occur following withdrawal of 
conivaptan therapy because of a compensatory rise in plasma 
AVP levels during the treatment period. With the upregulated 
AVP, both renal water retention and thirst may, once again, 
be excessively stimulated to result in hyponatremia. Indeed, 
Burnier et al (1999) previously reported that the aquaretic 
effect of conivaptan led to a transient negative ﬂ  uid balance 
when ﬂ  uid restriction was enforced, but rapidly became 
positive when the restriction was lifted. The requirement for 
water restriction during and following conivaptan treatment 
must be further examined.
In addition to rebound hyponatremia, the long-term 
effects of the compensatory rise in plasma AVP levels on 
V1B, and to a lesser extent, V1A receptors are unknown.
Although dual V1A/V2 receptor antagonism by conivap-
tan is potentially valuable in the management of congestive 
heart failure, data on its long-term effects on cardiovascular 
morbidity and mortality and overall improvement in quality 
of life and survival are lacking. Of interest, there is evidence 
to suggest that compared to placebo, intravenous administra-
tion of conivaptan to hypervolemic hyponatremic patients 
with underlying heart failure may be associated with a 
higher frequency of adverse cardiac events, atrial dysrhyth-
mias, and sepsis (Astellas Pharma US, Inc. 2007). The use 
of conivaptan in CHF patients must therefore be carefully 
weighed and should be limited to those with the greatest 
beneﬁ  ts to risks ratios.
Due to relatively limited data, another concern that remains 
unanswered, but must be examined, is the long-term effect of 
conivaptan on renal function. It is conceivable that excessive 
aquaresis with the use of conivaptan in some patients may 
lead to clinically signiﬁ  cant hypovolemia, hypotension, and 
subsequent acute tubular necrosis and kidney injury.
Limitations
It must be noted that current data have only included patients 
with chronic conditions associated with euvolemic and hyper-
volemic hyponatremia including patients with congestive 
heart failure. No data on the use of conivaptan in acute or 
severe hyponatremia (ie, [Na+]  115 mEq/L or hyponatremia 
with associated serious neurological sequelae) are available. 
A major concern for the use of conivaptan in critical condi-
tions or severe symptomatic hyponatremia is the potential 
for inaccurate predictions for the correction rate of serum 
[Na+] where prompt and precise corrections are key factors 
in assuring positive outcomes.
Conclusions
To date, V2 antagonism to induce aquaresis appears to be 
the most physiological approach to correct hyponatremia 
associated with dysregulated AVP. Intravenous conivaptan 
is the ﬁ  rst dual V1A/V2 receptor antagonist approved by 
the FDA for the treatment of euvolemic and hypervolemic 
hyponatremia in hospitalized patients. However, the use 
of conivaptan cannot be routinely recommended for CHF 
patients due to insufﬁ  cient efﬁ  cacy and safety data.
Although conivaptan has been shown to be an effective 
aquaretic with short-term use, its use is not without limi-
tations. Adverse effects reported with short-term use are 
Table 4 Limitations to the use of conivaptan
•  Data on efﬁ  cacy and safety for use in severe or symptomatic hyponatremia, or both, are lacking
•  Concurrent water restriction may be necessary to ensure optimal results
•  Known, potentially serious adverse effects:
  –  Orthostatic  hypotension
  –  Hypokalemia
•  Potential adverse effects based on the drug’s mechanism of action and pharmacokinetics:
    – Osmotic demyelination syndrome
    – Upregulation of endothelin and neurohormonal systems including the renin-angiotensin-aldosterone and sympathetic nervous system
  –  Rebound  hyponatremia
    – Hypothermia with peripheral vasodilatation
  –  Bleeding  complications
  –  Renal  failure
  –  Liver  failure
•  Unknown long-term effects:
    – Overstimulation of V1B, and to a lesser extent, V1A due to upregulated AVP
    – Long-term outcomes including efﬁ  cacy and safety with chronic use, quality of life and survival beneﬁ  ts
Abbreviation: AVL, arginine vasopressin.Therapeutics and Clinical Risk Management 2008:4(2) 325
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typically minimal, but may include serious effects including 
hypokalemia, orthostatic hypotension, and unexpectedly 
rapid serum [Na+] correction. Data to support the chronic 
use of conivaptan are currently lacking. Nevertheless, 
long-term use of conivaptan may eventually prove to be 
problematic due to its multiple drug-drug interactions. 
Finally, it must be noted that the aquaretic effect induced 
by conivaptan is not prolonged when the medication is 
discontinued.
Careful patient selection, avoidance of combined use with 
conventional diuretics, and close monitoring may reduce com-
plication rates with the use of conivaptan. The decision to use 
conivaptan over traditional therapeutic options for euvolemic 
and hypervolemic hyponatremic patients must be individualized 
while our current understanding of the systemic and long-term 
effects of dual V1A/V2 receptor antagonism is limited.
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